STOCK TITAN

Arvinas Inc - ARVN STOCK NEWS

Welcome to our dedicated news page for Arvinas (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arvinas's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arvinas's position in the market.

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.96%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.36%
Tags
management
-
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.47%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.95%
Tags
clinical trial
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.39%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.77%
Tags
earnings
Arvinas Inc

Nasdaq:ARVN

ARVN Rankings

ARVN Stock Data

2.81B
55.84M
2.56%
97.25%
11.64%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
New Haven

About ARVN

arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.